

Population: Women ages 67-85 who suffered a fracture and had either a bone mineral density test or received an osteoporosis prevention prescription.

Measurement Range: Bone mineral density test, 2 years prior to fracture or received a prescription in the 6 months after fracture.

Required Process/Codes: Must include the bone mineral density test and results. CPT: 76977-77078; 77080-77081; 77085-77086. Qualifying prescriptions include bisphosphonates: alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid, calcitonin, teriparatide, denosumab, and raloxifene.

Exclusions: Documented fracture of face, skull, finger or toe. BMD test during 24 months prior to the fracture, dispensed/active prescription to treat osteoporosis during 12 months prior to fracture, Claim/encounter for osteoporosis therapy during 12 months prior to fracture. Patients 67 and older in LTC, SNF, with advanced illness or frailty in prior or current measurement year.